Chugai's Tecentriq (atezolizumab) and Avastin (bevacizumab) Receive MHLW's Approval as 1L Treatment for Unresectable Hepatocellular Carcinoma
Shots:
- The approval is based on P-lll IMbrave150 study assessing Tecentriq (1200mg) and Avastin (100 mg/4 mL and 400 mg/16 mL) vs sorafenib in 501 patients in a ratio (2:1) with HCC- prior not treated with systemic therapy
- Result of IMbrave150 study: Reduction in risk of death (42%)- reduction in the risk of disease worsening (41%)- published in NEJM
- The dual regimen has received the MHLW’s PR based on the positive data showing improvement of prognosis- subsequently led to the approval seven months after the filing of the application
Ref: Roche | Image: Chugai
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com